JOHN R STUELPNAGEL Insider Trading $TXG 10x Genomics, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for JOHN R STUELPNAGEL.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of JOHN R STUELPNAGEL. JOHN R STUELPNAGEL is Senior V.P. of Operations in ILLUMINA INC ($ILMN) and Sr VP of Operations & COO in ILLUMINA INC ($ILMN) and VP Business Development in ILLUMINA INC ($ILMN) and Director in 10x Genomics, Inc. ($TXG).
JOHN R STUELPNAGEL in 10x Genomics, Inc.
Trading Symbol: TXGIndustry: LABORATORY ANALYTICAL INSTRUMENTS [3826]
Position of JOHN R STUELPNAGEL: Director
Holdings: 427,891 shares
Latest Transaction: May 05 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of JOHN R STUELPNAGEL in 10x Genomics, Inc.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 05 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 198.09 | 100 | 19,809 | 420,991 | 421.1 K to 421 K (-0.02 %) |
May 05 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 194.90 | 100 | 19,490 | 421,091 | 421.2 K to 421.1 K (-0.02 %) |
May 05 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 193.84 | 300 | 58,152 | 421,191 | 421.5 K to 421.2 K (-0.07 %) |
May 05 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 192.54 | 2,200 | 423,583 | 421,491 | 423.7 K to 421.5 K (-0.52 %) |
May 05 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 191.83 | 2,880 | 552,462 | 423,691 | 426.6 K to 423.7 K (-0.68 %) |
May 05 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 190.53 | 1,320 | 251,504 | 426,571 | 427.9 K to 426.6 K (-0.31 %) |
May 05 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 189.25 | 600 | 113,551 | 427,891 | 428.5 K to 427.9 K (-0.14 %) |
Apr 19 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 195.74 | 300 | 58,723 | 428,491 | 428.8 K to 428.5 K (-0.07 %) |
Apr 19 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 194.83 | 1,393 | 271,394 | 428,791 | 430.2 K to 428.8 K (-0.32 %) |
Apr 19 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 193.86 | 1,600 | 310,172 | 430,184 | 431.8 K to 430.2 K (-0.37 %) |
Apr 19 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 192.85 | 926 | 178,578 | 431,784 | 432.7 K to 431.8 K (-0.21 %) |
Apr 19 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 191.85 | 681 | 130,650 | 432,710 | 433.4 K to 432.7 K (-0.16 %) |
Apr 19 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 190.70 | 1,500 | 286,056 | 433,391 | 434.9 K to 433.4 K (-0.34 %) |
Apr 19 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 189.97 | 1,100 | 208,971 | 434,891 | 436 K to 434.9 K (-0.25 %) |
Apr 02 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 185.90 | 600 | 111,542 | 435,991 | 436.6 K to 436 K (-0.14 %) |
Apr 02 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 185.22 | 3,487 | 645,844 | 436,591 | 440.1 K to 436.6 K (-0.79 %) |
Apr 02 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 184.22 | 2,272 | 418,539 | 440,078 | 442.4 K to 440.1 K (-0.51 %) |
Apr 02 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 183.19 | 700 | 128,233 | 442,350 | 443.1 K to 442.4 K (-0.16 %) |
Apr 02 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 181.83 | 200 | 36,365 | 443,050 | 443.3 K to 443.1 K (-0.05 %) |
Apr 02 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 180.28 | 241 | 43,446 | 443,250 | 443.5 K to 443.3 K (-0.05 %) |
Mar 18 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 174.50 | 400 | 69,798 | 443,491 | 443.9 K to 443.5 K (-0.09 %) |
Mar 18 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 173.28 | 400 | 69,313 | 443,891 | 444.3 K to 443.9 K (-0.09 %) |
Mar 18 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 172.29 | 1,266 | 218,114 | 444,291 | 445.6 K to 444.3 K (-0.28 %) |
Mar 18 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 171.27 | 500 | 85,637 | 445,557 | 446.1 K to 445.6 K (-0.11 %) |
Mar 18 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 170.09 | 813 | 138,281 | 446,057 | 446.9 K to 446.1 K (-0.18 %) |
Mar 18 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 169.27 | 1,100 | 186,199 | 446,870 | 448 K to 446.9 K (-0.25 %) |
Mar 18 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 167.98 | 920 | 154,540 | 447,970 | 448.9 K to 448 K (-0.20 %) |
Mar 18 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 166.80 | 601 | 100,247 | 448,890 | 449.5 K to 448.9 K (-0.13 %) |
Mar 18 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 165.80 | 800 | 132,637 | 449,491 | 450.3 K to 449.5 K (-0.18 %) |
Mar 18 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 164.88 | 700 | 115,416 | 450,291 | 451 K to 450.3 K (-0.16 %) |
Feb 03 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 178.98 | 200 | 35,796 | 465,991 | 466.2 K to 466 K (-0.04 %) |
Feb 03 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 178.16 | 300 | 53,447 | 466,191 | 466.5 K to 466.2 K (-0.06 %) |
Feb 03 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 177.23 | 1,202 | 213,035 | 466,491 | 467.7 K to 466.5 K (-0.26 %) |
Feb 03 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 176.14 | 2,304 | 405,821 | 467,693 | 470 K to 467.7 K (-0.49 %) |
Feb 03 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 175.38 | 3,094 | 542,624 | 469,997 | 473.1 K to 470 K (-0.65 %) |
Feb 03 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 174.14 | 400 | 69,656 | 473,091 | 473.5 K to 473.1 K (-0.08 %) |
Jan 21 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 182.78 | 376 | 68,726 | 473,491 | 473.9 K to 473.5 K (-0.08 %) |
Jan 21 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 181.49 | 900 | 163,343 | 473,867 | 474.8 K to 473.9 K (-0.19 %) |
Jan 21 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 180.27 | 1,206 | 217,406 | 474,767 | 476 K to 474.8 K (-0.25 %) |
Jan 21 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 179.28 | 1,608 | 288,285 | 475,973 | 477.6 K to 476 K (-0.34 %) |
Jan 21 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 178.31 | 1,110 | 197,925 | 477,581 | 478.7 K to 477.6 K (-0.23 %) |
Jan 21 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 176.57 | 900 | 158,910 | 478,691 | 479.6 K to 478.7 K (-0.19 %) |
Jan 21 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 175.79 | 1,400 | 246,103 | 479,591 | 481 K to 479.6 K (-0.29 %) |
Jan 06 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 141.61 | 100 | 14,161 | 480,991 | 481.1 K to 481 K (-0.02 %) |
Jan 06 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 140.94 | 900 | 126,847 | 481,091 | 482 K to 481.1 K (-0.19 %) |
Jan 06 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 139.88 | 5,200 | 727,386 | 481,991 | 487.2 K to 482 K (-1.07 %) |
Jan 06 2021 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 138.91 | 1,300 | 180,588 | 487,191 | 488.5 K to 487.2 K (-0.27 %) |
Dec 18 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 151.24 | 300 | 45,371 | 488,491 | 488.8 K to 488.5 K (-0.06 %) |
Dec 18 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 149.36 | 801 | 119,633 | 488,791 | 489.6 K to 488.8 K (-0.16 %) |
Dec 18 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 148.51 | 3,098 | 460,068 | 489,592 | 492.7 K to 489.6 K (-0.63 %) |
Dec 18 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 147.68 | 2,200 | 324,905 | 492,690 | 494.9 K to 492.7 K (-0.44 %) |
Dec 18 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 146.78 | 1,101 | 161,606 | 494,890 | 496 K to 494.9 K (-0.22 %) |
Nov 19 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 136.97 | 1,100 | 150,667 | 503,491 | 504.6 K to 503.5 K (-0.22 %) |
Nov 19 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 136.20 | 4,424 | 602,525 | 504,591 | 509 K to 504.6 K (-0.87 %) |
Nov 19 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 135.41 | 1,576 | 213,400 | 509,015 | 510.6 K to 509 K (-0.31 %) |
Nov 19 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 133.18 | 400 | 53,270 | 510,591 | 511 K to 510.6 K (-0.08 %) |
Nov 04 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 139.03 | 500 | 69,517 | 510,991 | 511.5 K to 511 K (-0.10 %) |
Nov 04 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 137.47 | 772 | 106,129 | 511,491 | 512.3 K to 511.5 K (-0.15 %) |
Nov 04 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 136.23 | 3,900 | 531,296 | 512,263 | 516.2 K to 512.3 K (-0.76 %) |
Nov 04 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 135.62 | 2,328 | 315,723 | 516,163 | 518.5 K to 516.2 K (-0.45 %) |
Oct 20 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 164.67 | 3,001 | 494,159 | 518,491 | 521.5 K to 518.5 K (-0.58 %) |
Oct 20 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 163.99 | 4,499 | 737,777 | 521,492 | 526 K to 521.5 K (-0.86 %) |
Oct 05 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 126.88 | 100 | 12,688 | 525,991 | 526.1 K to 526 K (-0.02 %) |
Oct 05 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 125.99 | 2,999 | 377,832 | 526,091 | 529.1 K to 526.1 K (-0.57 %) |
Oct 05 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 125.51 | 3,700 | 464,390 | 529,090 | 532.8 K to 529.1 K (-0.69 %) |
Oct 05 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 124.21 | 701 | 87,071 | 532,790 | 533.5 K to 532.8 K (-0.13 %) |
Sep 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 123.48 | 700 | 86,433 | 533,491 | 534.2 K to 533.5 K (-0.13 %) |
Sep 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 122.88 | 2,265 | 278,317 | 534,191 | 536.5 K to 534.2 K (-0.42 %) |
Sep 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 121.64 | 813 | 98,891 | 536,456 | 537.3 K to 536.5 K (-0.15 %) |
Sep 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 120.62 | 3,322 | 400,696 | 537,269 | 540.6 K to 537.3 K (-0.61 %) |
Sep 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 119.67 | 400 | 47,866 | 540,591 | 541 K to 540.6 K (-0.07 %) |
Sep 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 123.48 | 700 | 86,433 | 533,491 | 534.2 K to 533.5 K (-0.13 %) |
Sep 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 122.88 | 2,265 | 278,317 | 534,191 | 536.5 K to 534.2 K (-0.42 %) |
Sep 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 121.64 | 813 | 98,891 | 536,456 | 537.3 K to 536.5 K (-0.15 %) |
Sep 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 120.62 | 3,322 | 400,696 | 537,269 | 540.6 K to 537.3 K (-0.61 %) |
Sep 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 119.67 | 400 | 47,866 | 540,591 | 541 K to 540.6 K (-0.07 %) |
Sep 03 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 115.46 | 100 | 11,546 | 540,991 | 541.1 K to 541 K (-0.02 %) |
Sep 03 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 114.88 | 1,881 | 216,090 | 541,091 | 543 K to 541.1 K (-0.35 %) |
Sep 03 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 113.91 | 3,517 | 400,625 | 542,972 | 546.5 K to 543 K (-0.64 %) |
Sep 03 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 112.96 | 2,002 | 226,144 | 546,489 | 548.5 K to 546.5 K (-0.37 %) |
Aug 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 105.61 | 762 | 80,476 | 548,491 | 549.3 K to 548.5 K (-0.14 %) |
Aug 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 104.78 | 5,938 | 622,197 | 549,253 | 555.2 K to 549.3 K (-1.07 %) |
Aug 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 102.99 | 800 | 82,388 | 555,191 | 556 K to 555.2 K (-0.14 %) |
Aug 05 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 100.96 | 300 | 30,289 | 555,991 | 556.3 K to 556 K (-0.05 %) |
Aug 05 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 99.62 | 2,532 | 252,242 | 556,291 | 558.8 K to 556.3 K (-0.45 %) |
Aug 05 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 99.08 | 4,668 | 462,516 | 558,823 | 563.5 K to 558.8 K (-0.83 %) |
Jul 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 90.15 | 100 | 9,015 | 563,491 | 563.6 K to 563.5 K (-0.02 %) |
Jul 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 89.17 | 3,626 | 323,325 | 563,591 | 567.2 K to 563.6 K (-0.64 %) |
Jul 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 88.52 | 3,774 | 334,086 | 567,217 | 571 K to 567.2 K (-0.66 %) |
Jul 02 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 89.08 | 100 | 8,908 | 570,991 | 571.1 K to 571 K (-0.02 %) |
Jul 02 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 87.99 | 3,896 | 342,792 | 571,091 | 575 K to 571.1 K (-0.68 %) |
Jul 02 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 87.08 | 3,504 | 305,113 | 574,987 | 578.5 K to 575 K (-0.61 %) |
Jun 18 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 90.13 | 1,057 | 95,267 | 578,491 | 579.5 K to 578.5 K (-0.18 %) |
Jun 18 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 89.48 | 2,648 | 236,948 | 579,548 | 582.2 K to 579.5 K (-0.45 %) |
Jun 18 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | S | 88.63 | 3,795 | 336,344 | 582,196 | 586 K to 582.2 K (-0.65 %) |
Jun 17 2020 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Option Exercise | A | 88.42 | 4,432 | 391,877 | 4,432 | |
Sep 16 2019 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Option Exercise | C | 0.00 | 49,634 | 0 | 49,634 | |
Sep 16 2019 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Option Exercise | C | 0.00 | 49,634 | 0 | 0 | |
Sep 16 2019 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Option Exercise | C | 0.00 | 223,304 | 0 | 223,304 | |
Sep 16 2019 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Option Exercise | C | 0.00 | 223,304 | 0 | 0 | |
Sep 16 2019 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Option Exercise | C | 0.00 | 1,253,823 | 0 | 1,253,823 | |
Sep 16 2019 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Option Exercise | C | 0.00 | 1,253,823 | 0 | 0 | |
Sep 16 2019 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Option Exercise | C | 0.00 | 457,289 | 0 | 457,289 | |
Sep 16 2019 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Option Exercise | C | 0.00 | 457,289 | 0 | 0 | |
Sep 16 2019 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Option Exercise | C | 0.00 | 121,686 | 0 | 121,686 | |
Sep 16 2019 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Option Exercise | C | 0.00 | 121,686 | 0 | 0 | |
Sep 16 2019 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Buy | J | 0.00 | 585,991 | 0 | 585,991 | 0 to 586 K |
Sep 16 2019 | TXG | 10x Genomics, Inc. | STUELPNAGEL JOHN R | Director | Sell | J | 0.00 | 585,991 | 0 | 0 | 586 K to 0 (-100.00 %) |
Page: 1